Salience attribution and its relationship to cannabis-induced psychotic symptoms

M A P Bloomfield, E Mouchlianitis, C J A Morgan, T P Freeman, H V Curran, J P Roiser, O D Howes

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

BACKGROUND: Cannabis is a widely used drug associated with increased risk for psychosis. The dopamine hypothesis of psychosis postulates that altered salience processing leads to psychosis. We therefore tested the hypothesis that cannabis users exhibit aberrant salience and explored the relationship between aberrant salience and dopamine synthesis capacity.

METHOD: We tested 17 cannabis users and 17 age- and sex-matched non-user controls using the Salience Attribution Test, a probabilistic reward-learning task. Within users, cannabis-induced psychotic symptoms were measured with the Psychotomimetic States Inventory. Dopamine synthesis capacity, indexed as the influx rate constant K i cer , was measured in 10 users and six controls with 3,4-dihydroxy-6-[18F]fluoro-l-phenylalanine positron emission tomography.

RESULTS: There was no significant difference in aberrant salience between the groups [F 1,32 = 1.12, p = 0.30 (implicit); F 1,32 = 1.09, p = 0.30 (explicit)]. Within users there was a significant positive relationship between cannabis-induced psychotic symptom severity and explicit aberrant salience scores (r = 0.61, p = 0.04) and there was a significant association between cannabis dependency/abuse status and high implicit aberrant salience scores (F 1,15 = 5.8, p = 0.03). Within controls, implicit aberrant salience was inversely correlated with whole striatal dopamine synthesis capacity (r = -0.91, p = 0.01), whereas this relationship was non-significant within users (difference between correlations: Z = -2.05, p = 0.04).

CONCLUSIONS: Aberrant salience is positively associated with cannabis-induced psychotic symptom severity, but is not seen in cannabis users overall. This is consistent with the hypothesis that the link between cannabis use and psychosis involves alterations in salience processing. Longitudinal studies are needed to determine whether these cognitive abnormalities are pre-existing or caused by long-term cannabis use.

Original languageEnglish
Pages (from-to)3383-3395
Number of pages13
JournalPsychological Medicine
Volume46
Issue number16
Early online date15 Sep 2016
DOIs
Publication statusPublished - 1 Dec 2016

Fingerprint

Cannabis
Psychotic Disorders
Dopamine
Marijuana Abuse
Corpus Striatum
Phenylalanine
Reward
Positron-Emission Tomography
Longitudinal Studies
Learning
Equipment and Supplies
Pharmaceutical Preparations

Keywords

  • Adult
  • Brain/diagnostic imaging
  • Cannabis/adverse effects
  • Case-Control Studies
  • Dihydroxyphenylalanine/analogs & derivatives
  • Dopamine/metabolism
  • Female
  • Humans
  • Male
  • Marijuana Abuse/diagnostic imaging
  • Neostriatum/diagnostic imaging
  • Positron-Emission Tomography
  • Psychoses, Substance-Induced/diagnostic imaging
  • Radiopharmaceuticals
  • Reward
  • Young Adult

Cite this

Bloomfield, M. A. P., Mouchlianitis, E., Morgan, C. J. A., Freeman, T. P., Curran, H. V., Roiser, J. P., & Howes, O. D. (2016). Salience attribution and its relationship to cannabis-induced psychotic symptoms. Psychological Medicine, 46(16), 3383-3395. https://doi.org/10.1017/S0033291716002051

Salience attribution and its relationship to cannabis-induced psychotic symptoms. / Bloomfield, M A P; Mouchlianitis, E; Morgan, C J A; Freeman, T P; Curran, H V; Roiser, J P; Howes, O D.

In: Psychological Medicine, Vol. 46, No. 16, 01.12.2016, p. 3383-3395.

Research output: Contribution to journalArticle

Bloomfield, MAP, Mouchlianitis, E, Morgan, CJA, Freeman, TP, Curran, HV, Roiser, JP & Howes, OD 2016, 'Salience attribution and its relationship to cannabis-induced psychotic symptoms', Psychological Medicine, vol. 46, no. 16, pp. 3383-3395. https://doi.org/10.1017/S0033291716002051
Bloomfield MAP, Mouchlianitis E, Morgan CJA, Freeman TP, Curran HV, Roiser JP et al. Salience attribution and its relationship to cannabis-induced psychotic symptoms. Psychological Medicine. 2016 Dec 1;46(16):3383-3395. https://doi.org/10.1017/S0033291716002051
Bloomfield, M A P ; Mouchlianitis, E ; Morgan, C J A ; Freeman, T P ; Curran, H V ; Roiser, J P ; Howes, O D. / Salience attribution and its relationship to cannabis-induced psychotic symptoms. In: Psychological Medicine. 2016 ; Vol. 46, No. 16. pp. 3383-3395.
@article{0e736944c1fc4f26bb5926f5d64f1a26,
title = "Salience attribution and its relationship to cannabis-induced psychotic symptoms",
abstract = "BACKGROUND: Cannabis is a widely used drug associated with increased risk for psychosis. The dopamine hypothesis of psychosis postulates that altered salience processing leads to psychosis. We therefore tested the hypothesis that cannabis users exhibit aberrant salience and explored the relationship between aberrant salience and dopamine synthesis capacity.METHOD: We tested 17 cannabis users and 17 age- and sex-matched non-user controls using the Salience Attribution Test, a probabilistic reward-learning task. Within users, cannabis-induced psychotic symptoms were measured with the Psychotomimetic States Inventory. Dopamine synthesis capacity, indexed as the influx rate constant K i cer , was measured in 10 users and six controls with 3,4-dihydroxy-6-[18F]fluoro-l-phenylalanine positron emission tomography.RESULTS: There was no significant difference in aberrant salience between the groups [F 1,32 = 1.12, p = 0.30 (implicit); F 1,32 = 1.09, p = 0.30 (explicit)]. Within users there was a significant positive relationship between cannabis-induced psychotic symptom severity and explicit aberrant salience scores (r = 0.61, p = 0.04) and there was a significant association between cannabis dependency/abuse status and high implicit aberrant salience scores (F 1,15 = 5.8, p = 0.03). Within controls, implicit aberrant salience was inversely correlated with whole striatal dopamine synthesis capacity (r = -0.91, p = 0.01), whereas this relationship was non-significant within users (difference between correlations: Z = -2.05, p = 0.04).CONCLUSIONS: Aberrant salience is positively associated with cannabis-induced psychotic symptom severity, but is not seen in cannabis users overall. This is consistent with the hypothesis that the link between cannabis use and psychosis involves alterations in salience processing. Longitudinal studies are needed to determine whether these cognitive abnormalities are pre-existing or caused by long-term cannabis use.",
keywords = "Adult, Brain/diagnostic imaging, Cannabis/adverse effects, Case-Control Studies, Dihydroxyphenylalanine/analogs & derivatives, Dopamine/metabolism, Female, Humans, Male, Marijuana Abuse/diagnostic imaging, Neostriatum/diagnostic imaging, Positron-Emission Tomography, Psychoses, Substance-Induced/diagnostic imaging, Radiopharmaceuticals, Reward, Young Adult",
author = "Bloomfield, {M A P} and E Mouchlianitis and Morgan, {C J A} and Freeman, {T P} and Curran, {H V} and Roiser, {J P} and Howes, {O D}",
year = "2016",
month = "12",
day = "1",
doi = "10.1017/S0033291716002051",
language = "English",
volume = "46",
pages = "3383--3395",
journal = "Psychological Medicine",
issn = "1469-8978",
publisher = "Cambridge University Press",
number = "16",

}

TY - JOUR

T1 - Salience attribution and its relationship to cannabis-induced psychotic symptoms

AU - Bloomfield, M A P

AU - Mouchlianitis, E

AU - Morgan, C J A

AU - Freeman, T P

AU - Curran, H V

AU - Roiser, J P

AU - Howes, O D

PY - 2016/12/1

Y1 - 2016/12/1

N2 - BACKGROUND: Cannabis is a widely used drug associated with increased risk for psychosis. The dopamine hypothesis of psychosis postulates that altered salience processing leads to psychosis. We therefore tested the hypothesis that cannabis users exhibit aberrant salience and explored the relationship between aberrant salience and dopamine synthesis capacity.METHOD: We tested 17 cannabis users and 17 age- and sex-matched non-user controls using the Salience Attribution Test, a probabilistic reward-learning task. Within users, cannabis-induced psychotic symptoms were measured with the Psychotomimetic States Inventory. Dopamine synthesis capacity, indexed as the influx rate constant K i cer , was measured in 10 users and six controls with 3,4-dihydroxy-6-[18F]fluoro-l-phenylalanine positron emission tomography.RESULTS: There was no significant difference in aberrant salience between the groups [F 1,32 = 1.12, p = 0.30 (implicit); F 1,32 = 1.09, p = 0.30 (explicit)]. Within users there was a significant positive relationship between cannabis-induced psychotic symptom severity and explicit aberrant salience scores (r = 0.61, p = 0.04) and there was a significant association between cannabis dependency/abuse status and high implicit aberrant salience scores (F 1,15 = 5.8, p = 0.03). Within controls, implicit aberrant salience was inversely correlated with whole striatal dopamine synthesis capacity (r = -0.91, p = 0.01), whereas this relationship was non-significant within users (difference between correlations: Z = -2.05, p = 0.04).CONCLUSIONS: Aberrant salience is positively associated with cannabis-induced psychotic symptom severity, but is not seen in cannabis users overall. This is consistent with the hypothesis that the link between cannabis use and psychosis involves alterations in salience processing. Longitudinal studies are needed to determine whether these cognitive abnormalities are pre-existing or caused by long-term cannabis use.

AB - BACKGROUND: Cannabis is a widely used drug associated with increased risk for psychosis. The dopamine hypothesis of psychosis postulates that altered salience processing leads to psychosis. We therefore tested the hypothesis that cannabis users exhibit aberrant salience and explored the relationship between aberrant salience and dopamine synthesis capacity.METHOD: We tested 17 cannabis users and 17 age- and sex-matched non-user controls using the Salience Attribution Test, a probabilistic reward-learning task. Within users, cannabis-induced psychotic symptoms were measured with the Psychotomimetic States Inventory. Dopamine synthesis capacity, indexed as the influx rate constant K i cer , was measured in 10 users and six controls with 3,4-dihydroxy-6-[18F]fluoro-l-phenylalanine positron emission tomography.RESULTS: There was no significant difference in aberrant salience between the groups [F 1,32 = 1.12, p = 0.30 (implicit); F 1,32 = 1.09, p = 0.30 (explicit)]. Within users there was a significant positive relationship between cannabis-induced psychotic symptom severity and explicit aberrant salience scores (r = 0.61, p = 0.04) and there was a significant association between cannabis dependency/abuse status and high implicit aberrant salience scores (F 1,15 = 5.8, p = 0.03). Within controls, implicit aberrant salience was inversely correlated with whole striatal dopamine synthesis capacity (r = -0.91, p = 0.01), whereas this relationship was non-significant within users (difference between correlations: Z = -2.05, p = 0.04).CONCLUSIONS: Aberrant salience is positively associated with cannabis-induced psychotic symptom severity, but is not seen in cannabis users overall. This is consistent with the hypothesis that the link between cannabis use and psychosis involves alterations in salience processing. Longitudinal studies are needed to determine whether these cognitive abnormalities are pre-existing or caused by long-term cannabis use.

KW - Adult

KW - Brain/diagnostic imaging

KW - Cannabis/adverse effects

KW - Case-Control Studies

KW - Dihydroxyphenylalanine/analogs & derivatives

KW - Dopamine/metabolism

KW - Female

KW - Humans

KW - Male

KW - Marijuana Abuse/diagnostic imaging

KW - Neostriatum/diagnostic imaging

KW - Positron-Emission Tomography

KW - Psychoses, Substance-Induced/diagnostic imaging

KW - Radiopharmaceuticals

KW - Reward

KW - Young Adult

U2 - 10.1017/S0033291716002051

DO - 10.1017/S0033291716002051

M3 - Article

VL - 46

SP - 3383

EP - 3395

JO - Psychological Medicine

JF - Psychological Medicine

SN - 1469-8978

IS - 16

ER -